D. Cooper

发表

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

P. Dormitzer, F. Polack, Stephen J. Thomas, 2020, The New England journal of medicine.

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

E. Walsh, A. Falsey, P. Dormitzer, 2020, Nature.

Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models.

D. Cooper, M. Guo, J. Kowalski, 2014, Vaccine.

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

P. Dormitzer, John L. Perez, D. Cooper, 2020, medRxiv.

A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine

E. Walsh, A. Falsey, P. Dormitzer, 2021, The Journal of infectious diseases.

In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation

D. Cooper, D. Clarke, S. Udem, 2009, Vaccine.

Assignment of Opsonic Values to Pneumococcal Reference Serum 007sp for Use in Opsonophagocytic Assays for 13 Serotypes

D. Cooper, M. Akkoyunlu, B. Plikaytis, 2016, Clinical and Vaccine Immunology.

Neutralizing Activity of BNT162b2-Elicited Serum

P. Dormitzer, K. Swanson, D. Cooper, 2021, The New England journal of medicine.

Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A.

Charles Y. Tan, D. Cooper, K. Jansen, 2022, Vaccine.

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults

D. Cooper, W. Gruber, M. Shiramoto, 2015, Human vaccines & immunotherapeutics.

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

P. Dormitzer, Stephen J. Thomas, N. Kitchin, 2021, The New England journal of medicine.

Synergistic Attenuation of Vesicular Stomatitis Virus by Combination of Specific G Gene Truncations and N Gene Translocations

R. M. Hendry, D. Cooper, J. Johnson, 2006, Journal of Virology.

Recombinant Vesicular Stomatitis Virus Vectors Expressing Herpes Simplex Virus Type 2 gD Elicit Robust CD4+ Th1 Immune Responses and Are Protective in Mouse and Guinea Pig Models of Vaginal Challenge

R. M. Hendry, D. Cooper, J. Eldridge, 2006, Journal of Virology.

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

M. Rämet, P. Dormitzer, N. Kitchin, 2021, The New England journal of medicine.

Flow Cytometric Assays to Quantify fHbp Expression and Detect Serotype Specific Capsular Polysaccharides on Neisseria meningitidis.

D. Cooper, A. Anderson, Jakob Loschko, 2019, Methods in molecular biology.

Attenuation of Recombinant Vesicular Stomatitis Virus-Human Immunodeficiency Virus Type 1 Vaccine Vectors by Gene Translocations and G Gene Truncation Reduces Neurovirulence and Enhances Immunogenicity in Mice

R. M. Hendry, D. Cooper, J. Johnson, 2007, Journal of Virology.

SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies.

A. Gurtman, D. Cooper, K. Jansen, 2017, Vaccine.

Post Hoc Analysis of a Randomized Double-Blind Trial of the Correlation of Functional and Binding Antibody Responses Elicited by 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines and Association with Nasopharyngeal Colonization

D. Greenberg, A. Gurtman, D. Cooper, 2014, Clinical and Vaccine Immunology.

Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine

E. Walsh, A. Falsey, P. Dormitzer, 2021, The Journal of infectious diseases.

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.

D. Cooper, R. Frenck, K. Jansen, 2017, Vaccine.

Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junction.

D. Cooper, M. Sidhu, J. Eldridge, 2006, Cellular immunology.

Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses.

D. Cooper, J. Eldridge, F. Nasar, 2004, Vaccine.

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants

P. Dormitzer, K. Swanson, D. Cooper, 2022, NPJ vaccines.

Correlation of Functional and Binding Antibody Responses

D. Greenberg, B. Gurion, A. Gurtman, 2014 .

Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report.

P. Dormitzer, K. Swanson, D. Cooper, 2021, The New England journal of medicine.

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

E. Walsh, A. Falsey, P. Dormitzer, 2020, The New England journal of medicine.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

P. Dormitzer, F. Polack, Stephen J. Thomas, 2021, The New England journal of medicine.

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

P. Dormitzer, John L. Perez, K. Swanson, 2020, Nature.

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

P. Dormitzer, John L. Perez, D. Cooper, 2021, Nature.

Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector

R. M. Hendry, D. Cooper, D. Clarke, 2006, Springer Seminars in Immunopathology.

A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.

E. Emini, D. Cooper, K. Jansen, 2015, Vaccine.

Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus

D. Cooper, K. Jansen, J. Ng, 2012, Human vaccines & immunotherapeutics.

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors

D. Cooper, K. Jansen, R. Donald, 2012, Human vaccines & immunotherapeutics.

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

E. Walsh, A. Falsey, P. Dormitzer, 2020, medRxiv.

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera

Vineet D. Menachery, P. Dormitzer, K. Swanson, 2021, bioRxiv.

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Vineet D. Menachery, P. Dormitzer, K. Swanson, 2021, bioRxiv.

Longitudinal analyses reveal age-specific immune correlates of COVID-19 severity

A. Amin, R. Edwards, D. Cooper, 2021, medRxiv.

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.

D. Cooper, K. Jansen, M. Nahm, 2011, Vaccine.

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

E. Walsh, A. Falsey, P. Dormitzer, 2021, The New England journal of medicine.

Herpes Simplex Virus Type 2 UL24 Gene Is a Virulence Determinant in Murine and Guinea Pig Disease Models

D. Long, D. Cooper, T. Zamb, 2005, Journal of Virology.

Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention

A. Gurtman, D. Cooper, K. Jansen, 2016, Expert review of vaccines.

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

P. Dormitzer, K. Swanson, D. Cooper, 2021, Nature.

Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine

P. Dormitzer, John L. Perez, K. Swanson, 2020, medRxiv.

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection

K. Swanson, D. Cooper, U. Şahin, 2022, bioRxiv.

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Vineet D. Menachery, P. Dormitzer, K. Swanson, 2021, Nature Medicine.

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age

N. Kitchin, A. Gurtman, S. Lockhart, 2023, The New England journal of medicine.

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

P. Dormitzer, N. Kitchin, A. Gurtman, 2022, The New England journal of medicine.

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

K. Swanson, D. Cooper, K. Jansen, 2022, Cell Host & Microbe.

13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model

D. Cooper, K. Jansen, Xinhong Yu, 2011, Human vaccines.

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine

K. Swanson, D. Cooper, K. Jansen, 2022, Nature Communications.

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

Stephen J. Thomas, N. Kitchin, S. Lockhart, 2023, The New England journal of medicine.

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

P. Dormitzer, F. Polack, N. Kitchin, 2021, medRxiv.

Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine

N. Kitchin, K. Swanson, D. Cooper, 2022, bioRxiv.

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants

P. Dormitzer, K. Swanson, D. Cooper, 2022, npj Vaccines.

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

E. Walsh, A. Falsey, P. Dormitzer, 2020, medRxiv.

Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

E. Walsh, A. Falsey, P. Dormitzer, 2021, Nature.

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

P. Dormitzer, K. Swanson, D. Cooper, 2021, NPJ vaccines.

A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults

P. Dormitzer, A. Gurtman, K. Swanson, 2022, The Journal of infectious diseases.

Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.

E. Walsh, A. Falsey, F. Polack, 2023, The New England journal of medicine.

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

P. Dormitzer, K. Swanson, D. Cooper, 2021, Research square.

Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)

A. Gurtman, D. Cooper, R. Frenck, 2019, Open forum infectious diseases.

The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery

A. Gurtman, D. Cooper, K. Jansen, 2018, Human vaccines & immunotherapeutics.

Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults

A. Gurtman, D. Cooper, K. Jansen, 2018, Human vaccines & immunotherapeutics.

Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

E. Walsh, A. Falsey, P. Dormitzer, 2021, Nature.

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

N. Kitchin, K. Swanson, D. Cooper, 2023, The New England journal of medicine.

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants

P. Dormitzer, K. Swanson, D. Cooper, 2021, The New England journal of medicine.

Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

P. Dormitzer, John L. Perez, K. Swanson, 2021, Nature.

BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants

P. Dormitzer, K. Swanson, D. Cooper, 2021, bioRxiv.

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.

S. Madhi, F. Polack, A. Gurtman, 2023, The New England journal of medicine.

Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study.

D. Cooper, K. Jansen, W. Gruber, 2016, The Journal of infection.

Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine

K. Swanson, D. Cooper, K. Jansen, 2022, bioRxiv.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Ping Li, P. Dormitzer, F. Polack, 2020 .

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine

P. Dormitzer, A. Gurtman, K. Swanson, 2021, The Journal of infectious diseases.